A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Clinical trial NCT06556199 · RECRUITING
Trial details
- NCT number
- NCT06556199
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-31
- Primary completion
- 2026-08-31
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.